Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Precision at the Margin: Innovations and Challenges in Intraoperative Molecular Imaging for Thoracic Surgery.

Journal of clinical medicine·2026
Same author

Post-discharge VTE prophylaxis after bariatric surgery: balancing bleeding risk and thrombosis prevention in 275,843 patients.

Surgical endoscopy·2026
Same author

Feasibility of intraoperative force quantification during robotic paraesophageal hernia repair: a prospective case series using integrated force-sensing technology.

Frontiers in surgery·2026
Same author

Things to Consider While Negotiating Your Contract: A Report From The Society of Thoracic Surgeons Workforce on Cardiothoracic Surgery Practice.

The Annals of thoracic surgery·2026
Same author

The 2026 American Association for Thoracic Surgery Expert Consensus Document: Evaluation and management of N2+ non-small cell lung cancer.

The Journal of thoracic and cardiovascular surgery·2026
Same author

An American College of Surgeons National Quality Improvement Collaborative to Enhance Lung Cancer Surgical Quality.

JAMA surgery·2026

Related Experiment Video

Updated: Jan 10, 2026

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
13:37

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies

Published on: March 12, 2014

30.4K

Neoadjuvant, Adjuvant, or Both? Optimizing Perioperative Systemic Therapy in Lung Cancer.

Emily P Rabinovich1, Linda W Martin2

  • 1Department of Surgery, University of Virginia Health System, Charlottesville, VA, USA. Electronic address: https://twitter.com/EmilyRabinovich.

Thoracic Surgery Clinics
|November 19, 2025
PubMed
Summary

Perioperative systemic therapy is revolutionizing resectable non-small cell lung cancer care. Novel therapies and biomarker-guided strategies offer improved survival over traditional chemotherapy alone.

Keywords:
Adjuvant chemotherapyAdjuvant immunotherapyLung cancerNeoadjuvant chemotherapyNon–small cell lung cancer (NSCLC)Perioperative systemic therapyTargeted therapy

More Related Videos

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

18.1K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K

Related Experiment Videos

Last Updated: Jan 10, 2026

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
13:37

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies

Published on: March 12, 2014

30.4K
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

18.1K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Pharmacology

Background:

  • Adjuvant chemotherapy alone has limitations in treating resectable non-small cell lung cancer.
  • There is a need for more effective perioperative treatment strategies.

Purpose of the Study:

  • To review the evolving landscape of perioperative systemic therapy for resectable non-small cell lung cancer.
  • To discuss the integration of novel therapies and biomarker-guided approaches.

Main Methods:

  • Literature review of perioperative systemic therapy in non-small cell lung cancer.
  • Discussion of adjuvant and neoadjuvant treatment settings.
  • Analysis of targeted therapies and immune checkpoint inhibitors.

Main Results:

  • Novel perioperative therapies demonstrate survival benefits.
  • Biomarker-guided approaches are crucial for personalized treatment.
  • Individualized and multidisciplinary strategies are essential.

Conclusions:

  • Perioperative systemic therapy significantly improves outcomes for resectable non-small cell lung cancer.
  • Optimal sequencing of novel agents is key.
  • Future directions involve further refining personalized treatment plans.